Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Abbott alleges former employee took trade secrets related to COVID-19 products

By Brian Buntz | November 3, 2020

Abbott Labs files order against ex-employee

[Image from Bill Oxford on Unsplash]

Abbott Laboratories has obtained a temporary restraining order against a former marketing executive.

The company alleges the former employee stole trade secrets, including details of upcoming COVID-19 products, before accepting a role at a competitor.

Virginia Kendall, a U.S. District Judge for the Northern District of Illinois, decided to grant the two-week restraining order against Jerome Clavel, a former Abbott vice president, for two weeks.

The judge agreed Clavel had access to trade secrets regarding “diagnostic and sensitive projects involving COVID-19 testing products.” The order will prevent Clavel from beginning to work for Bio-Rad Laboratories, a life sciences manufacturer involved in drug discovery and manufacturing. Clavel’s last day at Abbott was Oct. 30. Clavel “failed to work out his employment parameters with a competitor in spite of Abbott’s long history of doing so,” Kendall wrote in the order.

The order also permits expedited discovery for Abbott to determine which information was allegedly stolen.

Abbott claims Clavel downloaded company materials onto at least five USB hard drives. It also alleges that he forwarded confidential information and market predictions to a personal email address. The emails reportedly included information about an Abbott COVID-19 test.

The order forces Clavel to surrender the USB drives within 24 hours and turn over sensitive emails within one week.

According to his LinkedIn profile, Clavel held the Abbott position for one year and seven months.


Filed Under: Drug Discovery
Tagged With: Abbot Laboratories, Bio-Rad, covid-19
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50